Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 13/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | YAP1 | P46937 | 1/20 | 0.53 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.53 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.53 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791003 | 0.80 | RXFP1 (0.65) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL6796384 | 0.79 | SMO (0.55) | KDRGRM4 | |
| SCHEMBL15528884 | 0.79 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL28681534 | 0.78 | RXFP1 (0.83) | RXFP1 | |
| SCHEMBL30360592 | 0.78 | KMT2A (0.71) | KDRBRAFGRM4 | |
| SCHEMBL28290705 | 0.78 | KMT2A (0.71) | KDRBRAFGRM4 | |
| SCHEMBL7606603 | 0.77 | CES1 (0.55) | KDRBRAFGRM4 | |
| SCHEMBL7086616 | 0.77 | RXFP1 (0.60) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL6794345 | 0.76 | RXFP1 (0.58) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL6795046 | 0.76 | RXFP1 (0.58) | RXFP1ABL1EGFRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | RXFP1 1420/4885ABL1 1839/4885EGFR 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.